Review of Cannabinoids and their Antiemetic Effectiveness
- 32 Downloads
Marijuana has been used for over 2 centuries. Its major psychoactive constituent, delta-9-tetrahydrocannabinol (THC) was isolated in 1964 and first used to control nausea and vomiting during chemotherapy in the 1970s.
THC has cardiovascular, pulmonary and endocrinological effects as well as actions on the central nervous system. Alterations in mood, memory, motor coordination, cognitive ability, sensorium, spatial- and self-perception are commonly experienced. The precise antiemetic mechanism is unknown. THC and nabilone act at a number of sites within the central nervous system. Cannabinoids have also been shown to inhibit prostaglandin synthesis in vitro.
In controlled clinical trials, THC is superior to placebo and prochlorperazine in antiemetic effectiveness. Effectiveness of THC correlates to a ‘high’ experienced by the patient. A variety of chemotherapy regimens respond to THC including high-dose methotrexate and the doxorubicin, cyclophosphamide, fluorouracil combination. Cisplatin is more resistant. Side effects are generally well tolerated but may limit THC use in the elderly or when high doses are administered.
Nabilone, a synthetic cannabinoid, is also an effective antiemetic which is more active than prochlorperazine in preventing chemotherapy-induced emesis, including cisplatin-containing regimens. Side effects are similar to THC and may be dose-limiting.
Levonantradol, another synthetic cannabinoid, is an effective antiemetic. It may provide more flexibility in the outpatient setting since it can be administered orally or intramuscularly. Most side effects are mild except for dysphoria which may be dose-limiting.
KeywordsProchlorperazine Nabilone Antiemetic Effect Tetrahydrocannabinol Antiemetic Activity
Unable to display preview. Download preview PDF.
- Agurell, S.; Levander, S.; Binder, M.; Bader-Bartfai, A.; Gustafsson, B.; Leander, K.; Lindgren, J.; Ohlsson, A. and Tobisson, B.: Pharmacokinetics of delta-8-tetrahydrocannabinol (Delta-6-tetrahydrocannabinol) in man after smoking — relations to physiological and psychological effects; in Braude and Szara (Eds) Pharmacology of Marihuana, pp.49–61 (Raven Press, New York 1976Google Scholar
- Chopra, G.S.: Studies on psycho-clinical aspects of long-term marijuana use in 124 cases. International Journal of The Addiction 8: 1015–1026 (1973)Google Scholar
- Einhorn, L.H.: Comparison of nabilone and placebo in patients receiving cancer chemotherapy. (Unpublished study, 1982.)Google Scholar
- Garb, S.; Beers, A.L. and Bograd, M.: Two-pronged studies of tetrahydrocannabinol (THC) prevention of vomiting from cancer chemotherapy. IRCS Medical Science 2: 203–204 (1980)Google Scholar
- Gralla, R.J.; Tyson, L.B.; Clark, R.A.; Bordin, L.A.; Kelsen, D.P. and Kalman, L.B.: Antiemetic trials with high dose metoclopramide: Superiority over THC, and preservation of efficacy in subsequent chemotherapy courses. Proceedings of the American Society of Clinical Oncology 1: 58 (1982)Google Scholar
- Hermbree, W.C.; Nahas, G.G. and Huang, H.F.S.: Changes in human spermatozoa associated with high dose marijuana smoking; in Nahas and Paton (Eds) Marihuana: Biological Effects, pp.429–439 (Pergamon Press, New York, 1979Google Scholar
- Homesley, H.D.; Gainey, J.; Jobson, V.W.; Spurr, C.; Welander, C.E.; Muss, H.B. and Kimball, J.: Failure of delta-9-tetrahydrocannabinol and prochlorperazine to control chemotherapy induced nausea and vomiting. Proceedings of the American Society of Clinical Oncology 1: 67 (1982) (Abstract).Google Scholar
- Jaffe, J.H.: Drug addiction and drug abuse; in Gilman, Goodman and Gilman (Eds) The Pharmacological Basis of Therapeutics, pp.561–563 (McMillan Publishing Company, New York 1980Google Scholar
- Jones, R.T.; Marihuana-induced ‘high’ influence of expectation, setting and previous drug experience. Pharmacology Review 23: 359–369 (1971)Google Scholar
- Lemberger, L.; Axelrod, J. and Kopin, I.J.: New York Academy of Science Conference on Marijuana. Abstract 12 1971Google Scholar
- London, S.W.; McCarthy, L.E.; and Borison, H.L.: Suppression of cancer chemotherapy induced vomiting in the cat by nabilone, a synthetic cannabinoid. Proceedings of the Society of Experimental Biological Medicine 160: 437–440 (1979)Google Scholar
- Long, A.; Mioduszeuski, J.; Natale, R.: A randomized double-blind crossover comparison of the antiemetic activity of levonantradol and prochlorperazine. Proceedings of the American Society of Clinical Oncology 1: 57 (1982) (Abstract).Google Scholar
- Mahajan, V.K. and Huber, G.L.: Marijuana’s effects on the cardiopulmonary system. Parts 1 and 2. Primary Cardiology 4(6): 54–59 1978 and ibid 4(7): 59–63 1978Google Scholar
- Martin, B.: Abnormal Psychology: Clinical and Scientific Perspectives, pp.507–508 (Holt, Rinehart and Winston, New York 1977Google Scholar
- Mechoulam, R. (Ed): Marihuana: Chemistry, Pharmacology and Metabolism (Academic Press, New York 1973Google Scholar
- Nagy, C.M.; Furnas, B.E.; Einhorn, L.H. and Bond, W.H.: Nabilone antiemetic cross-over study in cancer chemotherapy patients. Proceedings of the American Association for Cancer Research 19: 30 (1978) (Abstract).Google Scholar
- Petersen, R.C.: Marijuana and Health. National Institute for Drug Abuse and Research. Monograph 31 pp.1–51 (Department of Health and Human Services, 1980Google Scholar
- Stambaugh, J.E.; McAdams, J. and Vreeland, F.: A phase II randomized trial of the antiemetic activity of levonantradol in cancer patients receiving chemotherapy. Proceedings of the American Society of Clinical Oncology 1: 62 (1982) (Abstract).Google Scholar
- Tyson, L.; Gralla, R.J.; Bordin, L.A.; Clark, R.A.; Bosl, G.J. and Young, C.W.: Levonantradol: Dose-finding studies and antiemetic trials in patients treated with cisplatin. Proceedings of the American Society of Clinical Oncolocy 1: 56 (1982) (Abstract).Google Scholar